

DURVALUMAB 10MG/KG

full description

INDICATIONS:

Locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on = 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy

DOSING:

Durvalumab IV infusion 10mg/kg day 1
14 day cycle

regimen name	DURVALUMAB
diagnosis	PDL1+ve >1% adeno NSCLC, PDL1+ve >50% treatment naive Squamous NSCLC, Squamous NSCLC (marker -ve/not tested)
version number	6.01

version no	amended date	amended by	summary
1	Wed Apr 17 2019 12:59:42 GMT+0100 (British Summer Time)	GAIL POVEY	
2	Fri Jan 15 2021 12:41:33 GMT+0000 (Greenwich Mean Time)	GAIL POVEY	Update route and note for giving sets
3	Tue Mar 23 2021 11:36:57 GMT+0000 (Greenwich Mean Time)	GAIL POVEY	Switch route back to IV infusion
4	Thu Dec 16 2021 15:42:47 GMT+0000 (Greenwich Mean Time)	Gail Povey	Random glucose added
5	Fri Dec 02 2022 10:18:00 GMT+0000 (Greenwich Mean Time)	Jason Hughes	Change all bloods to 7 days (leave TSH and T4 at 28 days)
6	Fri May 10 2024 10:42:31 GMT+0100 (British Summer Time)	Jason Hughes	Change critical test expiries
6.01	Wed Jul 10 2024 09:59:09 GMT+0100 (British Summer Time)	Gail Povey	Replaced dose reduction guidance with hyperlink to COIN document.

Treatment day: 1 day type: O slots: 6

drug name	route	vehicle	dose	dose calc	infus. time	frequency	duration	start time	line	fluid vol..	fluid calc
critical test:	HB100 7D, HAEMOGLOBIN >100 7D , range: 100-> 172										
critical test:	PLT100 7D, PLATELETS>100 7D , range: 100-> 600										
critical test:	WBC2 7D, WBC>2 7D , range: 2-> 11										
critical test:	NEUT1.5 7D, NEUTROPHILS >1.5 7D , range: 1.5-> 7.5										
critical test:	CR1.5 7D, CREATININE <1.5 x ULN 7 DAYS , range: 40-> 200										
critical test:	BIL1.57D, BILIRUBIN <1.5 x ULN 7 DAYS , range: 0-> 32										
critical test:	ALT<3 7D, ALT<3 x ULN 7 DAYS , range: 0-> 123										
critical test:	RBG 7D, Random blood glucose 7days , range: 3-> 12										
critical test:	T4 28D, Free T4 28 days , range: 11-> 25										
critical test:	TSH 28D, TSH 28 days , range: 0.27-> 4.2										
DURVALUMAB (Imfinzi)	IV Infusion	Sodium chloride 0.9%w/v	10 mg	WEIGHT				00:00		0	Dose
note:	IV infusion over 60 min. Use low-protein binding 0.2 or 0.22 micron in-line filter										
SODIUM CHLORIDE 0.9%W/V (FLUSH	IV Infusion	None	100 ml	FLAT				01:00		100	Fixed
note:	IV Infusion over 10 min										

Treatment day: 14 day type: X slots: 0

drug name	route	vehicle	dose	dose calc	infus. time	frequency	duration	start time	line	fluid vol..	fluid calc
review											

CLINICAL DETAILS

Please check the latest version of the Summary of Product Characteristics for the most up-to-date information on dose reductions, warnings and side effects.

For renal and hepatic dose reductions please check link to COIN in the clinical decision support tab above.

ADD NOTE="If to be combined with chemotherapy Durvalumab should be given prior to chemotherapy on the same day

HbA1C must be checked at the start of treatment but if a result is not available for the first cycle go ahead with treatment and ensure a result obtained before the next cycle. Blood glucose should be checked at each cycle unless otherwise stated by prescriber. If the result is >12mmol/L refer to Glycaemia protocol. "

<https://nhswales365.sharepoint.com/sites/SBUClinicalPathways/COIN/Forms/AllItems.aspx?id=%2Fsites%2FSBUClinicalPathways%2FCOIN%2FCLINICAL%20SPECIALTIES%2FOncology%2FChemocare%20Information%2FCID4892%20Dose%20Reco>



Regimen Entry		Pharmacist - PSU	
		Date	
Regimen		Pharmacist - QA	
		Date	
Regimen Verified		Consultant	
		Date	
		Medical Director	
		Date	